Ardelyx (NASDAQ: ARDX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.220 | -0.210 | 0.0100 | ||||
REV | 870.000K | 468.000K | -402.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Ardelyx (NASDAQ: ARDX) through any online brokerage.
Other companies in Ardelyx’s space includes: Alzamend Neuro (NASDAQ:ALZN), Anixa Biosciences (NASDAQ:ANIX), Fortress Biotech (NASDAQ:FBIO), HOOKIPA Pharma (NASDAQ:HOOK) and Galectin Therapeutics (NASDAQ:GALT).
The latest price target for Ardelyx (NASDAQ: ARDX) was reported by Piper Sandler on Thursday, May 19, 2022. The analyst firm set a price target for 3.00 expecting ARDX to rise to within 12 months (a possible 393.26% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Ardelyx (NASDAQ: ARDX) is $0.6082 last updated Today at July 5, 2022, 4:46 PM UTC.
There are no upcoming dividends for Ardelyx.
Ardelyx’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for Ardelyx.
Ardelyx is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.